LAUSR

References 1 Misitzis A, Beatson M, Weinstock MA. Response to: a randomized, open, controlled trial of tretinoin 0.05% cream vs. low-dose oral isotretinoin for the treatment of field cancerization. Int J Dermatol 2019. 2 Schmitt JV, Miot HA. Actinic keratosis: a clinical and epidemiological revision. An Bras Dermatol 2012; 87: 425–34. 3 Ulrich C, Jurgensen JS, Degen A, et al. Prevention of nonmelanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161(Suppl 3): 78–84. 4 Sanchez G, Nova J, Rodriguez-Hernandez AE, et al. Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database Syst Rev 2016; 7: CD011161. 5 Ianhez M, Fleury LF Jr, Miot HA, et al. Retinoids for prevention and treatment of actinic keratosis. An Bras Dermatol 2013; 88: 585–93. 6 Sumita JM, Miot HA, Soares JLM, et al. Tretinoin (0.05% cream vs. 5% peel) for photoaging and field cancerization of the forearms: randomized, evaluator-blinded, clinical trial. J Eur Acad Dermatol Venereol 2018; 32: 1819–26. 7 Ianhez M, Fleury Junior LF, Bagatin E, et al. The reliability of counting actinic keratosis. Arch Dermatol Res 2013; 305: 841–4. 8 Ianhez M, Pinto SA, Miot HA, et al. A randomized, open, controlled trial of tretinoin 0.05% cream vs. low-dose oral isotretinoin for the treatment of field cancerization. Int J Dermatol 2019; 58: 365–73. 9 Weinstock MA, Bingham SF, Digiovanna JJ, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012; 132: 1583–90.